Literature DB >> 344287

Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.

M T Bakowski, E Macdonald, R F Mould, P Cawte, J Sloggem, A Barrett, V Dalley, K A Newton, G Westbury, S E James, K Hellmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 344287     DOI： 10.1016/0360-3016(78)90125-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  6 in total

1.  Responses of liver metastases to radiotherapy and razoxane.

Authors:  K Hellmann; M Goold; N Higgins; R H Phillips
Journal:  J R Soc Med       Date:  1992-03       Impact factor: 5.344

Review 2.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

Review 3.  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.

Authors:  Philip Riley; Anne-Marie Glenny; Fang Hua; Helen V Worthington
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

4.  Adjuvant chemotherapy in head and neck cancer.

Authors:  P M Stell; N S Rawson
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

5.  Reduced survival with radiotherapy and razoxane compared with radiotherapy alone for inoperable lung cancer in a randomised double-blind trial.

Authors:  C E Newman; R Cox; C H Ford; J R Johnson; D R Jones; M Wheaton
Journal:  Br J Cancer       Date:  1985-05       Impact factor: 7.640

6.  Combination therapy of a mouse sarcoma using razoxane and electron irradiation.

Authors:  M B Grimshaw; R W Davies; W S Hall
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.